PT-141 (Bremelanotide) Research Guide: Melanocortin Receptor Mechanisms

PT-141 (Bremelanotide) represents a cyclic heptapeptide analog that selectively activates melanocortin-4 receptors (MC4R). Research indicates this melanocortin receptor agonist demonstrates unique structural stability and signaling mechanisms in laboratory studies.

["melanocortin receptors" "cyclic peptides" "MC4R signaling" "peptide stability" "neurological research" "metabolic studies"]
PT-141 (Bremelanotide) Research Guide: Melanocortin Receptor Mechanisms

Introduction to PT-141 (Bremelanotide)

PT-141, also known as Bremelanotide, is a synthetic cyclic heptapeptide analog of α-melanocyte stimulating hormone (α-MSH) that has garnered significant research interest for its selective melanocortin-4 receptor (MC4R) activation properties1. This research peptide, derived from the melanocortin II (MT-II) structure, exhibits enhanced stability and specificity compared to its linear counterparts, making it valuable for investigating melanocortin receptor mechanisms in controlled laboratory environments.

Melanocortin Receptor System Overview

The melanocortin system consists of five G-protein coupled receptors (MC1R-MC5R) that respond to melanocortin peptides derived from pro-opiomelanocortin (POMC)2. Among these, the MC4R has been extensively studied for its role in various physiological processes, including energy homeostasis, feeding behavior, and autonomic functions. Research suggests that MC4R activation initiates complex intracellular signaling cascades involving cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA) pathways3.

MC4R Distribution and Function

Studies have identified MC4R expression in multiple brain regions, including the hypothalamus, brainstem, and spinal cord4. The receptor appears to play crucial roles in metabolic regulation, with research indicating its involvement in glucose homeostasis, lipid metabolism, and insulin sensitivity. Laboratory investigations have demonstrated that MC4R activation influences neuronal excitability and neurotransmitter release in specific brain circuits.

PT-141 Structural Characteristics

The cyclic structure of PT-141 distinguishes it from linear melanocortin peptides and contributes to its enhanced stability and receptor selectivity5. The peptide's sequence (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH) incorporates several modifications that enhance its pharmacological properties compared to native melanocortins.

Cyclic vs Linear Peptide Stability

Research has shown that cyclic peptides generally exhibit superior resistance to enzymatic degradation compared to their linear counterparts6. The cyclization constrains the peptide backbone, reducing conformational flexibility and potentially protecting against proteolytic cleavage. This structural advantage is particularly relevant for peptide stability research, as it may influence storage requirements and experimental protocols.

Structural-Activity Relationships

Investigations into PT-141's structure-activity relationships have revealed that specific amino acid modifications contribute to its MC4R selectivity. The incorporation of D-phenylalanine at position 7 and the lactam bridge formation between aspartic acid and lysine residues appear to be critical for receptor binding affinity and selectivity profiles.

Melanocortin-4 Receptor Activation Mechanisms

PT-141's interaction with MC4R involves a complex binding mechanism that differs from other melanocortin receptor subtypes. Research indicates that the peptide binds to the extracellular domain of MC4R, inducing conformational changes that activate intracellular signaling pathways7.

G-Protein Coupling and Signal Transduction

Upon PT-141 binding, MC4R couples primarily to Gs proteins, leading to adenylyl cyclase activation and subsequent cAMP elevation. This increase in intracellular cAMP activates protein kinase A (PKA), which phosphorylates various downstream targets including CREB (cAMP response element-binding protein). Studies suggest this signaling cascade influences gene transcription and cellular responses.

Alternative Signaling Pathways

Recent research has indicated that MC4R may also couple to other G-protein subtypes, including Gq/11, leading to phospholipase C activation and inositol phosphate production. These alternative pathways may contribute to the diverse physiological effects observed in melanocortin receptor research.

Research Applications in Neurological Studies

PT-141's selective MC4R activation has made it valuable for investigating neurological mechanisms in controlled laboratory settings. Research has explored its effects on neuronal signaling, synaptic plasticity, and neural circuit function.

Central Nervous System Research

Laboratory studies have examined PT-141's influence on various brain regions, particularly those involved in autonomic control and behavioral regulation. Research suggests the peptide may affect neurotransmitter systems, including dopaminergic and noradrenergic pathways, through MC4R-mediated mechanisms.

Neuroplasticity Investigations

Some research has investigated PT-141's potential effects on neuroplasticity markers and synaptic function. Studies in animal models have explored whether MC4R activation influences dendritic spine formation, synaptic strength, and neural network connectivity.

Metabolic Research Applications

The role of MC4R in metabolic regulation has made PT-141 a valuable research tool for investigating energy homeostasis and metabolic signaling pathways. Laboratory studies have examined its effects on glucose metabolism, lipid oxidation, and insulin sensitivity.

Energy Balance Studies

Research has utilized PT-141 to investigate MC4R's role in energy expenditure and metabolic rate regulation. Studies suggest that MC4R activation may influence thermogenesis, physical activity levels, and substrate utilization in experimental models.

Glucose Homeostasis Research

Investigations have explored PT-141's effects on glucose metabolism and insulin signaling pathways. Research indicates that MC4R activation may influence hepatic glucose production, peripheral glucose uptake, and pancreatic function in laboratory settings.

Research Methodologies and Considerations

When working with PT-141 in research settings, several methodological considerations are important for obtaining reliable results. Proper reconstitution procedures and storage conditions are essential for maintaining peptide integrity.

Experimental Design Considerations

Research protocols should account for PT-141's pharmacokinetic properties, including its onset of action, duration of effect, and potential accumulation with repeated dosing. Dose-response relationships should be carefully established for each experimental model system.

Control and Vehicle Considerations

Appropriate control groups are essential in PT-141 research, including vehicle controls and potentially inactive analogs. The choice of vehicle and administration route can significantly influence experimental outcomes and should be carefully considered in study design.

Storage and Stability Considerations

PT-141's stability characteristics are important considerations for research applications. Like other modified peptides, proper storage conditions are essential for maintaining biological activity. Research indicates that cyclic peptides may have different stability profiles compared to linear sequences, potentially requiring adjusted storage protocols.

Temperature and pH Stability

Studies have examined PT-141's stability under various temperature and pH conditions. Research suggests that the cyclic structure may provide enhanced stability compared to linear peptides, but specific storage recommendations should be followed to ensure peptide integrity throughout experimental periods.

Future Research Directions

Ongoing research continues to explore PT-141's mechanisms and potential applications in various experimental models. Future investigations may focus on understanding tissue-specific MC4R signaling, identifying novel downstream targets, and developing improved analytical methods for studying melanocortin receptor function.

Mechanistic Studies

Advanced research techniques, including cryo-electron microscopy and advanced spectroscopic methods, may provide deeper insights into PT-141's binding mechanisms and receptor activation processes. These studies could enhance understanding of structure-activity relationships and guide the development of new research tools.

Conclusion

PT-141 (Bremelanotide) represents a valuable research tool for investigating melanocortin-4 receptor mechanisms and related physiological processes. Its unique cyclic structure provides enhanced stability compared to linear peptides, while its selective MC4R activation offers insights into melanocortin signaling pathways. As with all research peptides, PT-141 should be used exclusively for research purposes only, with appropriate safety protocols and regulatory compliance. Continued investigation of this peptide may contribute to advancing our understanding of melanocortin receptor biology and related physiological systems.

References

  1. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction Int J Impot Res (2004)
  2. Cone RD. Studies on the physiological functions of the melanocortin system Endocr Rev (2006)
  3. Mountjoy KG, Mortrud MT, Low MJ, Simerly RB, Cone RD. Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain Mol Endocrinol (1994)
  4. Kishi T, Aschkenasi CJ, Lee CE, Mountjoy KG, Saper CB, Elmquist JK. Expression of melanocortin 4 receptor mRNA in the central nervous system of the rat J Comp Neurol (2003)
  5. Hadley ME, Hruby VJ. Melanotropins and the melanocortin receptors: new opportunities in drug discovery Eur J Pharmacol (2005)
  6. Craik DJ, Fairlie DP, Liras S, Price D. The future of peptide-based drugs Chem Biol Drug Des (2013)
  7. Yang YK, Fong TM, Dickinson CJ, Mao C, Li JY, Tota MR, Mosley R, Van Der Ploeg LH, Gantz I. Molecular determinants of ligand binding to the human melanocortin-4 receptor Biochemistry (2000)